{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05558345",
            "orgStudyIdInfo": {
                "id": "20-001564"
            },
            "secondaryIdInfos": [
                {
                    "id": "K01DA051329",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/K01DA051329"
                }
            ],
            "organization": {
                "fullName": "University of California, Los Angeles",
                "class": "OTHER"
            },
            "briefTitle": "Expression of Stress Markers During Meth Treatment (EXPRESS+)",
            "officialTitle": "Expression of Stress Markers in MSM Living With HIV Receiving Contingency Management for Methamphetamine Use Disorder",
            "acronym": "EXPRESS+",
            "therapeuticArea": [
                "Infectious Diseases",
                "Other"
            ],
            "study": "expression-of-stress-markers-during-meth-treatment-express"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-09-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-03-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-09-21",
            "studyFirstSubmitQcDate": "2022-09-23",
            "studyFirstPostDateStruct": {
                "date": "2022-09-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Michael J. Li, PhD, MPH",
                "investigatorTitle": "Assistant Professor In-Residence",
                "investigatorAffiliation": "University of California, Los Angeles"
            },
            "leadSponsor": {
                "name": "University of California, Los Angeles",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.",
            "detailedDescription": "This is a within-subjects, two-arm study with 35 HIV-positive people assigned male at birth receiving contingency management for treatment of methamphetamine use disorder and 20 HIV-positive people assigned male at birth serving as a non-substance-using healthy control (N=55 total). HIV-positive participants with methamphetamine use disorder who meet the eligibility criteria will be assigned to the contingency management treatment group. HIV-positive participants who do not use substances and meet the specific criteria will be assigned to the non-substance-using control group. Participants will be observed over 8 weeks, with another follow-up 4 weeks thereafter."
        },
        "conditionsModule": {
            "conditions": [
                "Substance-Related Disorders",
                "HIV"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 55,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Contingency Management for Methamphetamine Reduction",
                    "type": "EXPERIMENTAL",
                    "description": "8 weeks of contingency management, twice weekly visits, with escalating rewards from $10 to $40 for negative urine tests",
                    "interventionNames": [
                        "Behavioral: Contingency Management"
                    ]
                },
                {
                    "label": "Non-substance-using Control",
                    "type": "NO_INTERVENTION",
                    "description": "Observational visits (no intervention) at baseline, Week 4, Week 8, and Week 12 for those who do not use methamphetamine."
                }
            ],
            "interventions": [
                {
                    "type": "BEHAVIORAL",
                    "name": "Contingency Management",
                    "description": "A positive reinforcement behavioral treatment with escalating rewards for consecutive negative urine tests, starting at $10 and capped at a maximum of $40 per negative result.",
                    "armGroupLabels": [
                        "Contingency Management for Methamphetamine Reduction"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Inflammatory and Type I IFN Gene Expression over 12 weeks",
                    "description": "Change in gene expression values -- based on count per million or reference gene normalized mRNA extracted from leukocytes and mapped to 53 a priori specified genes -- averaged over 4 times points using mixed linear regression",
                    "timeFrame": "every 4 weeks, at baseline, Week 4, Week 8, and Week 12"
                },
                {
                    "measure": "Change in Methamphetamine Use over 12 weeks",
                    "description": "Change in odds of methamphetamine use -- based on qualitative urine test result -- over 12 weeks.",
                    "timeFrame": "twice weekly for 8 weeks with 4-week follow-up in the contingency management group; once every 4 weeks over 12 weeks for the control group."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in HIV Viral Suppression over 12 weeks",
                    "description": "Change in odds of viral suppression -- based on viral load cut-off of \\< 200 c/mL blood -- over 12 weeks",
                    "timeFrame": "Once every 4 weeks over 12 weeks (i.e., baseline, Week 4, Week 8, Week 12)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nFor Contingency Management:\n\n1. Assigned male sex at birth\n2. 18 to 45 years of age\n3. Reports having sex with men in the past 12 months.\n4. HIV-positive (confirmed by certification or by HIV rapid test)\n5. Has an HIV care provider (last seen in the past 12 months)\n6. Has a current antiretroviral prescription\n7. Meets the DSM-5 criteria for methamphetamine use disorder using SCID-5\n8. Urine test is positive for methamphetamine within 30 days of their screening visit\n9. Seeking treatment for methamphetamine use disorder.\n10. Ability to attend twice weekly appointments for drug testing and treatment\n\nFor Non-substance-using Control:\n\n1. Assigned male sex at birth\n2. 18 to 45 years of age\n3. Reports having sex with men in the past 12 months.\n4. HIV-positive (confirmed by certification or by HIV rapid test)\n5. Has an HIV care provider (last seen in the past 12 months)\n6. Has a current antiretroviral prescription\n\nExclusion Criteria:\n\nFor Contingency Management:\n\n1. Identifies as (cis- or transgender) female\n2. Reports another current or past substance use disorder\n3. Reports being in another intervention or clinical trial for substance use\n4. Positive test for opioids, cocaine, and/or MDMA\n\nFor Non-substance-using Control:\n\n1. Identifies as (cis- or transgender) female\n2. Positive test for methamphetamine, opioids, cocaine, and/or MDMA.\n3. Reports substance use (methamphetamine, opioids, cocaine, MDMA, hallucinogens, heavy alcohol use, and/or tobacco) in the past 6 months\n4. Reports past or current substance use disorder",
            "healthyVolunteers": true,
            "sex": "MALE",
            "genderBased": true,
            "genderDescription": "Assigned male sex at birth but does not identify as female.",
            "minimumAge": "18 Years",
            "maximumAge": "45 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Michael J Li, PhD",
                    "role": "CONTACT",
                    "phone": "3107948530",
                    "email": "mjli@mednet.ucla.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Michael J Li, PhD",
                    "affiliation": "UCLA Department of Family Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCLA Vine Street Clinic",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90038",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Michael J Li, PhD",
                            "role": "CONTACT",
                            "phone": "310-794-8530",
                            "email": "mjli@mednet.ucla.edu"
                        },
                        {
                            "name": "Michael J Li, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Landing Page for Enrollment",
                    "url": "https://vinestreet.uclacbam.org/study/express+"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "It is possible that future collaborators of the PI (e.g., other UCLA investigators) may conduct secondary analyses on the data to answer other research questions. The other investigator may submit a concept for a research question and hypothesis to be tested using the data. This would require PI approval of a concept, and co-authorship/involvement of the PI on the study.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF"
            ],
            "timeFrame": "After the PI completes publication of their specific aims and any secondary outcomes, data will be available for at least 3 years thereafter.",
            "accessCriteria": "Submission and PI approval of a concept sheet"
        }
    },
    "documentSection": {
        "largeDocumentModule": {
            "largeDocs": [
                {
                    "typeAbbrev": "Prot_SAP_ICF",
                    "hasProtocol": true,
                    "hasSap": true,
                    "hasIcf": true,
                    "label": "Study Protocol, Statistical Analysis Plan, and Informed Consent Form",
                    "date": "2022-07-08",
                    "uploadDate": "2022-09-21T16:23",
                    "filename": "Prot_SAP_ICF_000.pdf",
                    "size": 419241
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                }
            ],
            "ancestors": [
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3522",
                    "name": "Acquired Immunodeficiency Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M18250",
                    "name": "HIV Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "asFound": "Substance-Related Disorders",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M11674",
                    "name": "Methamphetamine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "CNSSti",
                    "name": "Central Nervous System Stimulants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}